Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy. (3rd April 2023)

• Record Type: Journal Article
• Authors: Ye, Tai-Wei; Wang, Dong-Dong; Lu, Wen-Feng; Xie, Ya-Ming; Xu, Fei-Qi; Fu, Tian-Wei; Zhang, Kang-Jun; Liu, Si-Yu; Xie, Gui-Lin; Cheng, Jian; Jiang, Kai; Xiao, Zun-Qiang; Yao, Wei-Feng; Shen, Guo-Liang; Liu, Jun-Wei; Huang, Dong-Sheng; Zhang, Cheng-Wu; Liang, Lei
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 17:Number 4(2023)
• Page Start: 395
• Page End: 403
• Publication Date: 2023-04-03
• Subjects: Hepatocellular carcinoma -- hepatectomy -- transcatheter arterial chemoembolization -- adjuvant therapy -- survival; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1080/17474124.2023.2192479
• Languages: English
• ISSNs: 1747-4124

Abstract

ABSTRACT: Background & aims: Although anatomical hepatectomy (AH) is widely used in the treatment of hepatocellular carcinoma (HCC), the prognosis is still unsatisfactory. The present study aimed to evaluate the survival benefit of adjuvant transcatheter arterial chemoembolization (TACE) for patients with HCC after AH. Methods: A total of 832 patients were stratified into with adjuvant TACE (443, 53.2%) and without adjuvant TACE group (389, 46.8%) AH. Propensity score matching (PSM) was performed to control for confounding factors, and multivariable Cox regression was performed to determine the independent risk factors. Results: After PSM, the results showed that the adjuvant TACE group had better overall survival (OS) and recurrence-free survival (RFS). Among the patients with tumor recurrence, adjuvant TACE was associated with a high rate of early-stage tumor at recurrence, a lower recurrence rate around the frontal margin and extrahepatic metastases, and a higher rate of receiving curative treatment. Multivariable Cox regression analysis showed that adjuvant TACE was an independent prognostic factor for OS (HR 0.673, P = 0.001) and RFS (HR 0.650, P = 0.001). Conclusions: Patients with HCC after AH can benefit from postoperative adjuvant TACE. Therefore, adjuvant TACE should be considered for patients with a high risk of recurrence.